A joint research team of DGIST (Daegu Gyeongbuk Institute of Science and Technology) have identified the early neuropathic mechanism of polyglutamine brain disease, one of the representative degenerative brain diseases, and suggested a way to restore. It is expected to accelerate the development of the early neuropathy treatment for a variety of degenerative brain diseases, including dementia, Parkinson’s disease and Lou Gehrig’s disease that are commonly known to be caused by toxic proteins.
DGIST (President, Sang Hyuk Son) announced on July 17, Monday, that a research team led by Professor Lee Sung-bae of the Department of Brain and Cognitive Sciences and a research team of Professor Daehee Hwang (Vice-Director of Center for Plant Aging Research, Institute for Basic Science) of the Department of New Biology, have identified the early neuropathic mechanism of dendritic-specific Golgi on neurodegenerative brain diseases in neuronal cells for the first time in the world.
The development of science and technology and the advancement of medical technology have increased the elderly population. Especially in Korea, one of the 10 elderly people aged 65 or older in recent years has been suffering from dementia. With the increasing number of patients suffering from intractable degenerative brain disease, many studies have been conducted to understand and treat brain diseases all over the world. However, the development of therapeutic agents is insufficient.
In particular, the patients who seek doctors after realizing that they have degenerative brain diseases are likely to have already damaged brain cells and it is difficult to expect an effective recovery by using a commercially available therapeutic agent. Therefore, it is essential to understand how degenerative brain disease progresses in the early stage.
The research teams led by Professor Sung Bae Lee and Professor Daehee Hwang have verified for the first time in the world that dendritic-specific Golgi, one of…